Targeted therapy in colorectal cancer: do we know enough?

Area of Science:

• Oncology
• Pharmacology
• Cancer Therapeutics

Background:

• Chemotherapy was the primary treatment for advanced solid tumors, including colorectal cancer.
• Recent advancements include targeted therapies like monoclonal antibodies and tyrosine kinase inhibitors.
• These novel agents aim to block specific cellular functions involved in cancer progression.

Purpose of the Study:

• To critically review recent developments in targeted therapies for solid tumors.
• To focus on the therapeutic approach for colorectal cancer.
• To analyze the efficacy and limitations of new targeted agents.

Main Methods:

• Critical review of existing literature on novel cancer agents.
• Analysis of preclinical data and clinical trial results.
• Comparison of targeted therapies with traditional chemotherapy and established targeted drugs.

Main Results:

• Targeted therapies show a strong biological and preclinical rationale.
• Clinical results are not consistently comparable to established targeted therapies like imatinib.
• Efficacy of new agents does not correlate with tumor molecular expression profiles.

Conclusions:

• The clinical efficacy of new targeted agents in solid tumors, including colorectal cancer, needs further debate and investigation.
• Reasons for suboptimal clinical outcomes despite strong preclinical data are explored.
• Further research is required to understand and improve the effectiveness of these revolutionary therapies.